Saeed Iqira, La Caze Adam, Hollmann Markus W, Shaw Paul N, Parat Marie-Odile
School of Pharmacy, University of Queensland, 20 Cornwall Street, Woolloongabba, Australia.
Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.
Curr Oncol Rep. 2021 Aug 27;23(11):123. doi: 10.1007/s11912-021-01121-y.
Opioids are administered to cancer patients although concerns have been raised that they may promote tumour growth or metastasis owing to their ability to suppress anti-cancer immunity. Tramadol has been reported to preserve or promote the immune response and may therefore be preferred to other opioids in cancer patients. We reviewed the literature documenting the immunomodulatory effects of tramadol.
Recent clinical evidence appears to confirm that tramadol possesses anti-inflammatory properties, and preserves some signalling cascades of the immune system relevant to anti-cancer defence. Tramadol is reported to promote or preserve immunity including natural killer cell activity which is important in anti-cancer defences.
尽管有人担心阿片类药物可能因其抑制抗癌免疫的能力而促进肿瘤生长或转移,但仍会给癌症患者使用阿片类药物。据报道,曲马多可维持或促进免疫反应,因此在癌症患者中可能比其他阿片类药物更受青睐。我们回顾了记录曲马多免疫调节作用的文献。
最近的临床证据似乎证实曲马多具有抗炎特性,并保留了一些与抗癌防御相关的免疫系统信号级联反应。据报道,曲马多可促进或维持免疫力,包括在抗癌防御中起重要作用的自然杀伤细胞活性。